Literature DB >> 23526548

Antibodies in epilepsy.

Cynthia M Correll1.   

Abstract

Antibody mediated limbic encephalitis is an increasingly recognized cause of seizures in cryptogenic epilepsy. Autoimmune encephalitis and epilepsy have been linked to both neuronal intracellular antibodies (GAD65, ANNA-1, and Ma) and neuronal cell surface antibodies (VGKC complex, NMDAR, AMPA, GABA-B, and GluR5). This article outlines the latest data on these various antibodies with a focus on their association with acute seizures in limbic encephalitis and likely increased risk for chronic epilepsy. There is mounting evidence that these antibodies may play a role in acute onset and chronic seizures in the general epilepsy population without manifesting typical limbic encephalitis symptoms. This review will discuss the data supporting early recognition and treatment options, beyond typical antiepileptic medications, necessary to improve outcomes in this epilepsy subgroup.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23526548     DOI： 10.1007/s11910-013-0348-1

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN： 1528-4042            Impact factor:   5.081


  63 in total

1.  Epilepsia partialis continua and frontal features as a debut of anti-Hu paraneoplastic encephalomyelitis with focal frontal encephalitis.

Authors:  J Porta-Etessam; J Ruiz-Morales; J M Millan; A Ramos; A Martínez-Salio; A Berbel-García
Journal:  Eur J Neurol       Date:  2001-07       Impact factor: 6.089

2.  Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients.

Authors:  F Graus; F Keime-Guibert; R Reñe; B Benyahia; T Ribalta; C Ascaso; G Escaramis; J Y Delattre
Journal:  Brain       Date:  2001-06       Impact factor: 13.501

3.  FDG-PET and MRI in potassium channel antibody-associated non-paraneoplastic limbic encephalitis: correlation with clinical course and neuropsychology.

Authors:  S Fauser; J Talazko; K Wagner; S Ziyeh; S Jarius; A Vincent; A Schulze-Bonhage
Journal:  Acta Neurol Scand       Date:  2005-05       Impact factor: 3.209

4.  The expanding clinical profile of anti-AMPA receptor encephalitis.

Authors:  F Graus; A Boronat; X Xifró; M Boix; V Svigelj; A García; A Palomino; L Sabater; J Alberch; A Saiz
Journal:  Neurology       Date:  2010-03-09       Impact factor: 9.910

5.  GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders.

Authors:  A Boronat; L Sabater; A Saiz; J Dalmau; F Graus
Journal:  Neurology       Date:  2011-03-01       Impact factor: 9.910

Review 6.  Serial 18F-fluoro-2-deoxy-D-glucose positron emission tomography and magnetic resonance imaging of paraneoplastic limbic encephalitis.

Authors:  Rainer Scheid; Thomas Lincke; Raymond Voltz; D Yves von Cramon; Osama Sabri
Journal:  Arch Neurol       Date:  2004-11

7.  Limbic encephalitis as a precipitating event in adult-onset temporal lobe epilepsy.

Authors:  C G Bien; H Urbach; J Schramm; B M Soeder; A J Becker; R Voltz; A Vincent; C E Elger
Journal:  Neurology       Date:  2007-09-18       Impact factor: 9.910

8.  N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes.

Authors:  Sarosh R Irani; Katarzyna Bera; Patrick Waters; Luigi Zuliani; Susan Maxwell; Michael S Zandi; Manuel A Friese; Ian Galea; Dimitri M Kullmann; David Beeson; Bethan Lang; Christian G Bien; Angela Vincent
Journal:  Brain       Date:  2010-06       Impact factor: 13.501

9.  Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy.

Authors:  Suvi Liimatainen; Maria Peltola; Lidia Sabater; Mahdi Fallah; Elham Kharazmi; Anna-Maija Haapala; Prasun Dastidar; Mikael Knip; Albert Saiz; Jukka Peltola
Journal:  Epilepsia       Date:  2009-10-08       Impact factor: 5.864

10.  Clinical analysis of anti-Ma2-associated encephalitis.

Authors:  Josep Dalmau; Francesc Graus; Alberto Villarejo; Jerome B Posner; Deborah Blumenthal; Brian Thiessen; Albert Saiz; Patricio Meneses; Myrna R Rosenfeld
Journal:  Brain       Date:  2004-06-23       Impact factor: 13.501
View more
  7 in total

Review 1.  Infections, inflammation and epilepsy.

Authors:  Annamaria Vezzani; Robert S Fujinami; H Steve White; Pierre-Marie Preux; Ingmar Blümcke; Josemir W Sander; Wolfgang Löscher
Journal:  Acta Neuropathol       Date:  2015-09-30       Impact factor: 17.088

2.  Paradox Lost: Exploring the Clinical-Radiologic Dissociation Seen in Anti-NMDA Receptor Encephalitis.

Authors:  Bernard S Chang
Journal:  Epilepsy Curr       Date:  2014-05       Impact factor: 7.500

3.  The Face (and Arm) of Treatment for Seizures in VGKC/LGI1 Antibody-Associated Limbic Encephalitis.

Authors:  Bernard S Chang
Journal:  Epilepsy Curr       Date:  2014-07       Impact factor: 7.500

4.  Admission diagnoses of patients later diagnosed with autoimmune encephalitis.

Authors:  Annette Baumgartner; Sebastian Rauer; Tilman Hottenrott; Frank Leypoldt; Friederike Ufer; Harald Hegen; Harald Prüss; Jan Lewerenz; Florian Deisenhammer; Oliver Stich
Journal:  J Neurol       Date:  2018-11-12       Impact factor: 4.849

5.  Loss of Autonoetic Awareness of Recent Autobiographical Episodes and Accelerated Long-Term Forgetting in a Patient with Previously Unrecognized Glutamic Acid Decarboxylase Antibody Related Limbic Encephalitis.

Authors:  Juri-Alexander Witt; Viola Lara Vogt; Guido Widman; Karl-Josef Langen; Christian Erich Elger; Christoph Helmstaedter
Journal:  Front Neurol       Date:  2015-06-09       Impact factor: 4.003

6.  Progressive limbic encephalopathy: Problems and prospects.

Authors:  Sadanandavalli Retnaswami Chandra; Roopa Seshadri; Yasha Chikabasaviah; Thomas Gregor Issac
Journal:  Ann Indian Acad Neurol       Date:  2014-04       Impact factor: 1.383

7.  Postencephalitic epilepsy in dogs with meningoencephalitis of unknown origin: Clinical features, risk factors, and long-term outcome.

Authors:  Adriana Kaczmarska; Roberto José-López; Michał Czopowicz; Kali Lazzerini; Guillaume Leblond; Catherine Stalin; Rodrigo Gutierrez-Quintana
Journal:  J Vet Intern Med       Date:  2020-01-28       Impact factor: 3.333
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.